XML 17 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenues:        
Total revenues $ 10,739 $ 6,483 $ 29,988 $ 19,437
Cost of sales (4,191) (3,403) (12,419) (10,048)
Gross profit 6,548 3,080 17,569 9,389
Operating expenses:        
Selling, general and administrative 6,964 5,781 20,231 19,077
Research and development 233 63 392 324
Total operating expenses 7,197 5,844 20,623 19,401
Loss from operations (649) (2,764) (3,054) (10,012)
Other income (expense):        
Interest expense, net (705) (793) (2,039) (2,348)
Loss on sale of assets (42) (326)
Other expense, net (884) (255) (884)
Total other income (expense), net (1,865) (2,956) (451) 714
Loss before income taxes (2,514) (5,720) (3,505) (9,298)
Income tax benefit, net 28 84
Net loss $ (2,514) $ (5,692) $ (3,505) $ (9,214)
Basic and diluted net loss per share of common stock $ (0.12) $ (0.28) $ (0.16) $ (0.47)
Weighted average number of shares of common stock outstanding, basic and diluted 21,709,392 20,273,347 21,283,078 19,806,759
Surface Pharmaceuticals [Member]        
Other income (expense):        
Investment losses $ (128) $ (230)
Gain on deconsolidation 5,320
Eton Pharmaceuticals [Member]        
Other income (expense):        
Investment losses (1,032) (1,237) (3,247) (1,453)
Gain on deconsolidation 5,725
Product Sales, Net [Member]        
Revenues:        
Total revenues 10,729 6,473 29,958 19,411
License Revenues [Member]        
Revenues:        
Total revenues $ 10 $ 10 $ 30 $ 26